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Background
Research in recent years has highlighted the interactions 
between cancer cells and stromal cells as crucial deter mi-
nants of cancer progression [1]. Stromal cells of the 
tumor microenvironment, which includes ﬁ broblasts, 
endothelial cells, immune cells and more, actively 
participate in the tumorigenic process and have become 
important therapeutic targets in cancer [2]. In addition to 
local stromal interactions within the tumor micro-
environ ment, tumors appear to have a systemic eﬀ ect 
that can inﬂ uence cancer progression, primarily via the 
stimulation of bone marrow cells [3].
In a previous study 3 years ago, McAllister and 
colleagues [4] reported that certain tumors (termed 
‘instigators’) can foster the growth of otherwise indolent 
tumors (termed ‘responders’) at a distant anatomical site 
via the activation and recruitment of bone marrow cells. 
However, the identity of the activated bone marrow cells 
and their speciﬁ c contribution had not been determined.
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Researchers from McAllister’s group at Brigham and 
Women’s Hospital have now determined the identity of 
the activated bone marrow cells responsible for stimu lat-
ing the growth of otherwise indolent tumor cells and 
further characterized the impact of the activated bone 
marrow cells on these responding tumors [5]. In addition, 
they have identiﬁ ed a molecular mechanism by which the 
activated bone marrow cells facilitate growth of the 
responding tumors.
Histological analysis of the responding tumors stimu-
lated by the bone marrow cells demonstrated a greater 
desmoplastic reaction with increased distribution of 
alpha-smooth muscle actin-positive myoﬁ broblasts and 
excess collagen deposition. Elkabets and colleagues [5] 
determined that the myoﬁ broblasts are not bone marrow 
derived; thus, the bone marrow cells are not diﬀ er en-
tiating into myoﬁ broblasts but rather activating the 
myoﬁ broblasts within the tumor microenvironment.
Fluorescence-activated cell sorting (FACS) analysis of 
the activated bone marrow cells identiﬁ ed them as a 
Sca1+cKit- population of hematopoietic progenitors. 
While this population of bone marrow cells also exists in 
mice bearing non-instigating tumors, only the Sca1+cKit-
population from mice bearing instigator tumors can 
stimulate the growth of responding tumors. Gene 
expression proﬁ ling of the Sca1+cKit- populations from 
instigator-bearing mice and non-instigator-bearing mice 
identiﬁ ed that the bone marrow cells from instigator-
bearing mice exhibit increased expression of granulin, a 
secreted growth factor of the epithelin family.
In the absence of activated bone marrow cells, recom-
binant granulin alone was able to stimulate the growth of 
indolent tumor cells with an accompanying desmoplastic 
reaction. Notably, assessment of granulin expression in 
human breast cancer samples demonstrated that high 
granulin expression is signiﬁ cantly correlated with the 
most aggressive breast tumor subtypes and reduced 
patient survival.
Viewpoint
Th e role of granulin in promoting tumorigenesis has 
been previously investigated [6] and its potential as a 
therapeutic target has been explored via the use of a 
monoclonal antibody against granulin, which was able to 
inhibit tumor growth in a dose-dependent manner [7]. 
However, many of these studies have focused on the 
function of granulin as expressed by cancer cells; the 
Abstract
 As appreciation grows for the contribution of the 
tumor microenvironment to the progression of 
cancer, new evidence accumulates to support 
that the participation of stromal cells can extend 
beyond the local environment. Recently, Elkabets 
and colleagues demonstrated a systemic interaction 
between cancer cells and distant bone marrow cells 
to support the growth of otherwise indolent tumor 
cells at a secondary site, raising thought-provoking 
questions regarding the involvement of stromal cells in 
maintaining metastatic dormancy.
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study by McAllister’s group [5] is the ﬁ rst to identify a 
stromal contribution of granulin to tumorigenesis.
Activated bone marrow cells expressing granulin are 
recruited to the tumor microenvironment to stimulate 
the growth of otherwise indolent tumor cells. Noting the 
hematopoietic source of granulin, this raises an interest-
ing question as to whether the assessment of granulin 
levels in the serum may serve as a prognostic marker for 
relapse in cancer patients. Additionally, one might also 
draw a parallel between the indolent responding tumors 
of these experiments and the dormant metastases of 
cancer patients. In this case, is bone marrow-derived 
granulin one of the factors responsible for waking up 
dormant metastases?
Osteopontin was previously identiﬁ ed as the molecule 
secreted by the instigator tumor, which activates the bone 
marrow cells [4]. Is the continued presence of the 
instigator tumor necessary to maintain activation of the 
bone marrow cells? Or do the bone marrow cells remain 
activated despite removal of the instigator tumor? Th e 
answers to these questions will have implications on the 
therapeutic eﬃ  cacy of primary tumor resection and 
additional measures that may need to be taken in order 
to suppress metastatic outgrowth. Even after primary 
tumor resection, there may be other sources of osteo-
pontin or additional mechanisms that activate bone 
marrow cells. A greater understanding of the mechanisms 
underlying bone marrow activation may have important 
clinical implications for maintaining metastatic dormancy.
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